{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:18:48Z","timestamp":1780611528736,"version":"3.54.1"},"reference-count":169,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2010]]},"DOI":"10.1016\/j.cellimm.2010.03.002","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T04:46:51Z","timestamp":1268110011000},"page":"96-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus"],"prefix":"10.1016","volume":"262","author":[{"given":"Mohamed L.","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"EL-Demellawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel Raouf Abou","family":"El-Azm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2010.03.002_bib1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/sj.bjc.6603649","article-title":"Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review","volume":"96","author":"Raza","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellimm.2010.03.002_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2893.2002.00329.x","article-title":"Hepatitis C: an epidemiological review","volume":"9","author":"Memon","year":"2002","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.cellimm.2010.03.002_bib3","unstructured":"Hepatitis E fact sheet (revised August 2004), Wkly. Epidemiol. Rec. 79 (2004) 314\u2013316."},{"key":"10.1016\/j.cellimm.2010.03.002_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2893.2009.01115.x","article-title":"Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality","volume":"16","author":"Lehman","year":"2009","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.cellimm.2010.03.002_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/ije\/dyp194","article-title":"Community transmission of hepatitis B virus in Egypt: results from a case-control study in Greater Cairo","volume":"38","author":"Paez Jimenez","year":"2009","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1572-0241.2008.01825.x","article-title":"Acute hepatitis C: a systematic review","volume":"103","author":"Kamal","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1089-3261(02)00077-6","article-title":"Current therapy for hepatitis C: pegylated interferon and ribavirin","volume":"7","author":"McHutchison","year":"2003","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.cellimm.2010.03.002_bib8","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1016\/S0264-410X(03)00529-2","article-title":"Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus","volume":"21","author":"Hilleman","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.cellimm.2010.03.002_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.med.52.1.29","article-title":"Current treatment strategies for chronic hepatitis B and C","volume":"52","author":"Lin","year":"2001","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cellimm.2010.03.002_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1189\/jlb.1208772","article-title":"Immune-based therapy for chronic hepatitis C","volume":"86","author":"Chang","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib11","doi-asserted-by":"crossref","unstructured":"Hepatitis C: global prevalence, Wkly. Epidemiol. Rec. 72 (1997) 341\u2013344.","DOI":"10.1484\/J.CDE.2.309057"},{"key":"10.1016\/j.cellimm.2010.03.002_bib12","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3748\/wjg.v13.i12.1770","article-title":"A comparative review of HLA associations with hepatitis B and C viral infections across global populations","volume":"13","author":"Singh","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cellimm.2010.03.002_bib14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(99)06527-7","article-title":"The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt","volume":"355","author":"Frank","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cellimm.2010.03.002_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2009.07.007","article-title":"Genotypic characterization of symptomatic hepatitis E virus (HEV) infections in Egypt","author":"Blackard","year":"2009","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib16","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3748\/wjg.15.1480","article-title":"Positional effect of mutations in 5\u2019UTR of hepatitis C virus 4a on patients\u2019 response to therapy","volume":"15","author":"El Awady","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib17","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1086\/315786","article-title":"Genetic epidemiology of hepatitis C virus throughout egypt","volume":"182","author":"Ray","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cellimm.2010.03.002_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2003.10.007","article-title":"Analysis of T cell responses against hepatitis C virus genotype 4 in Egypt","volume":"40","author":"Elrefaei","year":"2004","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib19","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04079","article-title":"Adaptive immune responses in acute and chronic hepatitis C virus infection","volume":"436","author":"Bowen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2010.03.002_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/MCG.0b013e31819f66e2","article-title":"Long-term outcomes after treatment with interferon and ribavirin in HCV patients","volume":"43","author":"Aronsohn","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.2009.01187.x","article-title":"New developments in the antiviral treatment of hepatitis C","volume":"97","author":"de Bruijne","year":"2009","journal-title":"Vox Sang."},{"key":"10.1016\/j.cellimm.2010.03.002_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1172\/JCI118842","article-title":"Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response","volume":"98","author":"Missale","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2010.03.002_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/jhep.2001.21162","article-title":"Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection","volume":"33","author":"Chang","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.194.10.1395","article-title":"Determinants of viral clearance and persistence during acute hepatitis C virus infection","volume":"194","author":"Thimme","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2010.03.002_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-2000-9946","article-title":"Interaction between the hepatitis C virus and the immune system","volume":"20","author":"Rehermann","year":"2000","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.cellimm.2010.03.002_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-2007-979468","article-title":"Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses","volume":"27","author":"Rehermann","year":"2007","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.cellimm.2010.03.002_bib27","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1172\/JCI39133","article-title":"Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence","volume":"119","author":"Rehermann","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2010.03.002_bib28","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bpg.2008.11.015","article-title":"Immunology of hepatitis B and hepatitis C virus infections","volume":"22","author":"Boonstra","year":"2008","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/08830180802432178","article-title":"Hepatitis C virus (HCV): a review of immunological aspects","volume":"27","author":"Irshad","year":"2008","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2169\/internalmedicine.45.1530","article-title":"Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity","volume":"45","author":"Kanto","year":"2006","journal-title":"Intern. Med."},{"key":"10.1016\/j.cellimm.2010.03.002_bib31","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1086\/315450","article-title":"Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C","volume":"181","author":"Gruner","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cellimm.2010.03.002_bib32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1098\/rstb.2000.0646","article-title":"Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers","volume":"355","author":"Lechner","year":"2000","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.cellimm.2010.03.002_bib33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.SMJ.0000118903.35704.30","article-title":"Hepatitis C infection: a clinical review","volume":"97","author":"Pearlman","year":"2004","journal-title":"South. Med. J."},{"key":"10.1016\/j.cellimm.2010.03.002_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/187152209789000687","article-title":"Plasticity of T cell differentiation and cytokine signature: a double-edged sword for immune responses","volume":"9","author":"Salem","year":"2009","journal-title":"Immunol. Endocr. Metab. Agents Med. Chem. (IEMAMC)"},{"issue":"Suppl. 3","key":"10.1016\/j.cellimm.2010.03.002_bib35","first-page":"S327","article-title":"Regulatory T cells in hepatitis C virus infection","volume":"37","author":"Chang","year":"2007","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-0-387-72005-0_22","article-title":"Myeloid-derived suppressor cells","volume":"601","author":"Nagaraj","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib38","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1158\/0008-5472.CAN-08-4625","article-title":"The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression","volume":"69","author":"Ilkovitch","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib39","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1128\/JVI.00649-07","article-title":"Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines","volume":"81","author":"Abe","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib40","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1371\/journal.pone.0000330","article-title":"Hepatitis C lipo-Viro-particle from chronically infected patients interferes with TLR4 signaling in dendritic cell","volume":"2","author":"Agaugue","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2010.03.002_bib41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1189\/jlb.0207128","article-title":"Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins","volume":"82","author":"Chang","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-3083.2005.01670.x","article-title":"Tissue localization of Toll-like receptors in biopsy specimens of liver from children infected with hepatitis C virus","volume":"62","author":"Mozer-Lisewska","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib43","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1440-1746.2006.04783.x","article-title":"Expression of Toll-like receptors in chronic hepatitis C virus infection","volume":"22","author":"Sato","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib44","doi-asserted-by":"crossref","first-page":"G15","DOI":"10.1152\/ajpgi.90512.2008","article-title":"Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis","volume":"296","author":"Stadlbauer","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000086657","article-title":"TLR signalling and the function of dendritic cells","volume":"86","author":"Hemmi","year":"2005","journal-title":"Chem. Immunol. Allergy"},{"issue":"Suppl. 3","key":"10.1016\/j.cellimm.2010.03.002_bib46","doi-asserted-by":"crossref","first-page":"iii44","DOI":"10.1136\/ard.2008.097964","article-title":"Phagocytosis and antigen presentation: a partnership initiated by Toll-like receptors","volume":"67","author":"Blander","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cellimm.2010.03.002_bib47","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2008.01.028","article-title":"Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication","volume":"48","author":"Broering","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ecl.2009.01.002","article-title":"Regulatory T cells: key players in tolerance and autoimmunity","volume":"38","author":"Chatila","year":"2009","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.cellimm.2010.03.002_bib49","doi-asserted-by":"crossref","first-page":"8832","DOI":"10.1073\/pnas.132254399","article-title":"CD25+CD4+ T cells contribute to the control of memory CD8+ T cells","volume":"99","author":"Murakami","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellimm.2010.03.002_bib50","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nri1485","article-title":"Regulatory T cells: friend or foe in immunity to infection?","volume":"4","author":"Mills","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cellimm.2010.03.002_bib51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2893.2009.01081.x","article-title":"Regulatory T cells and viral liver disease","volume":"16","author":"Alatrakchi","year":"2009","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.cellimm.2010.03.002_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.virol.2007.06.030","article-title":"Antigen-induced regulatory T cells in HBV chronically infected patients","volume":"368","author":"Barboza","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-6143.2009.02743.x","article-title":"Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation","author":"Carpentier","year":"2009","journal-title":"Am. J. Transplant"},{"key":"10.1016\/j.cellimm.2010.03.002_bib54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"Diaz-Montero","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cellimm.2010.03.002_bib55","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.canlet.2008.03.012","article-title":"Myeloid-derived suppressor cell role in tumor-related inflammation","volume":"267","author":"Dolcetti","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cellimm.2010.03.002_bib56","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib57","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.4049\/jimmunol.0803831","article-title":"IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients","volume":"182","author":"Mandruzzato","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib58","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1053\/j.gastro.2008.06.032","article-title":"Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway","volume":"135","author":"Haile","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/hep.23054","article-title":"Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor","author":"Hoechst","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells","volume":"135","author":"Hoechst","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib61","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archneurol.2009.16","article-title":"Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis","volume":"66","author":"Oh","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.trim.2008.01.005","article-title":"Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation","volume":"19","author":"Wang","year":"2008","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib63","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.transproceed.2005.03.131","article-title":"IL-2 antagonists: the European perspective","volume":"37","author":"Platz","year":"2005","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.cellimm.2010.03.002_bib64","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/14796694.4.4.457","article-title":"Optimizing denileukin diftitox (Ontak) therapy","volume":"4","author":"Duvic","year":"2008","journal-title":"Future Oncol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib65","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-0-387-68969-2_20","article-title":"Regulatory T cells: a new frontier in cancer immunotherapy","volume":"622","author":"Barnett","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib66","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/0008-5472.CAN-08-4323","article-title":"Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells","volume":"69","author":"Xin","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib67","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2141.2008.07433.x","article-title":"Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells","volume":"144","author":"Fei","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib68","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","article-title":"The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies","volume":"69","author":"Ozao-Choy","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib69","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.4049\/jimmunol.165.12.6723","article-title":"Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes","volume":"165","author":"Apolloni","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib70","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.4049\/jimmunol.161.10.5313","article-title":"Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+\/Gr-1+ cells","volume":"161","author":"Bronte","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib71","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellimm.2010.03.002_bib72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11912-009-0014-6","article-title":"Myeloid-derived suppressor cells: a novel therapeutic target","volume":"11","author":"Ko","year":"2009","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.cellimm.2010.03.002_bib73","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients","volume":"15","author":"Ko","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib74","doi-asserted-by":"crossref","first-page":"8270","DOI":"10.1158\/1078-0432.CCR-08-0165","article-title":"Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma","volume":"14","author":"Kusmartsev","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib75","first-page":"184","article-title":"Interaction of indoleamine-2,3-dioxyagnase and CD4+CD25+ regulatory T cells in tumor immune escape","volume":"28","author":"Wang","year":"2009","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.cellimm.2010.03.002_bib76","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/187153006778250019","article-title":"Targeting tumor-related immunosuppression for cancer immunotherapy","volume":"6","author":"Frumento","year":"2006","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"10.1016\/j.cellimm.2010.03.002_bib77","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.4049\/jimmunol.0803314","article-title":"Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques","volume":"182","author":"Boasso","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib78","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood-2007-10-116111","article-title":"Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells","volume":"111","author":"Lob","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2010.03.002_bib79","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1158\/0008-5472.CAN-08-2106","article-title":"Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib80","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/eji.200636181","article-title":"TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation","volume":"36","author":"Cottalorda","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib81","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.4049\/jimmunol.180.8.5291","article-title":"MyD88-dependent pathway in T cells directly modulates the expansion of colitogenic CD4+ T cells in chronic colitis","volume":"180","author":"Tomita","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib82","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.vaccine.2008.11.013","article-title":"The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice","volume":"27","author":"Salem","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.cellimm.2010.03.002_bib83","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ecam\/nek010","article-title":"Role of Toll-like receptors in adjuvant-augmented immune therapies","volume":"3","author":"Seya","year":"2006","journal-title":"Evid. Based Complement Altern. Med."},{"key":"10.1016\/j.cellimm.2010.03.002_bib84","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.smim.2006.12.004","article-title":"TLR signaling","volume":"19","author":"Kawai","year":"2007","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib85","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2006.11.007","article-title":"Expression and function of Toll-like receptors in T lymphocytes","volume":"19","author":"Kabelitz","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib86","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.intimp.2009.01.027","article-title":"Regulatory T cells and Toll-like receptors: what is the missing link?","volume":"9","author":"Dai","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib87","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/187152809788462581","article-title":"Modulation of regulatory T cells in health and disease: role of toll-like receptors","volume":"8","author":"Nyirenda","year":"2009","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"10.1016\/j.cellimm.2010.03.002_bib88","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2567.2008.02871.x","article-title":"Toll-like receptor signalling on Tregs: to suppress or not to suppress?","volume":"124","author":"van Maren","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib89","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/intimm\/dxl136","article-title":"TLR9 ligand enhances proliferation of rat CD4+ T cell and modulates suppressive activity mediated by CD4+ CD25+ T cell","volume":"19","author":"Chiffoleau","year":"2007","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.imlet.2006.12.007","article-title":"CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells","volume":"108","author":"LaRosa","year":"2007","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.cellimm.2010.03.002_bib91","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1172\/JCI25439","article-title":"Toll-like receptor 2 controls expansion and function of regulatory T cells","volume":"116","author":"Sutmuller","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2010.03.002_bib92","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1113401","article-title":"Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function","volume":"309","author":"Peng","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2010.03.002_bib93","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.4049\/jimmunol.0802430","article-title":"Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine","volume":"182","author":"Ko","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib94","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.cji.0000156828.75196.0d","article-title":"Defining the antigen-specific T-cell response to vaccination and poly(I:C)\/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity","volume":"28","author":"Salem","year":"2005","journal-title":"J. Immunother."},{"key":"10.1016\/j.cellimm.2010.03.002_bib95","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.4049\/jimmunol.0801829","article-title":"Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)","volume":"182","author":"Salem","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib96","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.onc.1210910","article-title":"TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours","volume":"27","author":"Conroy","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.cellimm.2010.03.002_bib97","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.4049\/jimmunol.175.12.8051","article-title":"Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells","volume":"175","author":"Crellin","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib98","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/j.1462-5822.2006.00731.x","article-title":"Bacterial flagellin inhibits T cell receptor-mediated activation of T cells by inducing suppressor of cytokine signalling-1 (SOCS-1)","volume":"8","author":"Okugawa","year":"2006","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib99","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ni1362","article-title":"Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c(+) lamina propria cells","volume":"7","author":"Uematsu","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cld.2008.03.003","article-title":"Hepatitis C and innate immunity: recent advances","volume":"12","author":"Szabo","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.cellimm.2010.03.002_bib101","first-page":"17","article-title":"Dendritic cells: translating innate to adaptive immunity","volume":"311","author":"Steinman","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib102","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/0470871628.ch17","article-title":"Dendritic cells: controllers of the immune system and a new promise for immunotherapy","volume":"252","author":"Banchereau","year":"2003","journal-title":"Novartis Found. Symp."},{"key":"10.1016\/j.cellimm.2010.03.002_bib103","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/ni722","article-title":"Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells","volume":"2","author":"Albert","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib104","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nri1592","article-title":"Dendritic cells as therapeutic vaccines against cancer","volume":"5","author":"Banchereau","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"Pt. 4","key":"10.1016\/j.cellimm.2010.03.002_bib105","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1099\/0022-1317-79-4-705","article-title":"Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus\/GB virus C in peripheral blood mononuclear cells","volume":"79","author":"Mellor","year":"1998","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib106","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(05)70114-6","article-title":"Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence?","volume":"5","author":"Pachiadakis","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cellimm.2010.03.002_bib107","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000050047","article-title":"Dendritic cells and chronic hepatitis virus carriers","volume":"44","author":"Akbar","year":"2001","journal-title":"Intervirology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib108","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.2741\/3146","article-title":"Virus associated innate immunity in liver","volume":"13","author":"Kanto","year":"2008","journal-title":"Front. Biosci."},{"issue":"Suppl. 3","key":"10.1016\/j.cellimm.2010.03.002_bib109","first-page":"S319","article-title":"Innate immunity in hepatitis C virus infection: interplay among dendritic cells, natural killer cells and natural killer T cells","volume":"37","author":"Kanto","year":"2007","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1745-7254.2008.00711.x","article-title":"Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma","volume":"29","author":"Xu","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.cellimm.2010.03.002_bib111","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.hepres.2005.12.010","article-title":"Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection","volume":"34","author":"Yakushijin","year":"2006","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib112","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1128\/JVI.79.7.3969-3978.2005","article-title":"Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon","volume":"79","author":"Breiman","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib113","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clim.2008.04.006","article-title":"Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients","volume":"128","author":"Chen","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib114","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.4049\/jimmunol.177.10.6758","article-title":"Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection","volume":"177","author":"Dolganiuc","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib115","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/01.tp.0000276960.35313.bf","article-title":"Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus","volume":"84","author":"Eid","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.cellimm.2010.03.002_bib116","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/j.1478-3231.2006.01357.x","article-title":"Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C","volume":"26","author":"He","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.cellimm.2010.03.002_bib117","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2893.2007.00904.x","article-title":"Defective response to Toll-like receptor 3 and 4 ligands by activated monocytes in chronic hepatitis C virus infection","volume":"15","author":"Villacres","year":"2008","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.cellimm.2010.03.002_bib118","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.22751","article-title":"Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells","volume":"49","author":"Wu","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib119","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.micinf.2009.02.008","article-title":"Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9","volume":"11","author":"Xie","year":"2009","journal-title":"Microbes Infect."},{"key":"10.1016\/j.cellimm.2010.03.002_bib120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11596-009-0310-2","article-title":"Expression of toll-like receptor 9 in peripheral blood mononuclear cells from patients with different hepatitis B and C viral loads","volume":"29","author":"Zhou","year":"2009","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci."},{"key":"10.1016\/j.cellimm.2010.03.002_bib121","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1542-3565(05)00702-0","article-title":"Natural killer cells in hepatitis C virus infection: from innate immunity to adaptive immunity","volume":"3","author":"Takehara","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib122","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/lt.20708","article-title":"Natural killer cells: primary target for hepatitis C virus immune evasion strategies?","volume":"12","author":"Golden-Mason","year":"2006","journal-title":"Liver Transpl."},{"key":"10.1016\/j.cellimm.2010.03.002_bib123","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1089\/vim.2006.0096","article-title":"T cell dysfunction by hepatitis C virus core protein involves PD-1\/PDL-1 signaling","volume":"20","author":"Yao","year":"2007","journal-title":"Viral. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib124","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2007.12.014","article-title":"Restoration of HCV-specific T cell functions by PD-1\/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment","volume":"48","author":"Urbani","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib125","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.4049\/jimmunol.180.7.4875","article-title":"Blockade of PD-1\/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model","volume":"180","author":"Lukens","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib126","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.4049\/jimmunol.180.6.3637","article-title":"Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences","volume":"180","author":"Golden-Mason","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib127","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1128\/JVI.02474-07","article-title":"High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome","volume":"82","author":"Kasprowicz","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.22337","article-title":"Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells","volume":"48","author":"Ebihara","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib129","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.173.10.6072","article-title":"Negative regulation of NK cell activities by inhibitory receptor CD94\/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection","volume":"173","author":"Jinushi","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib130","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4049\/jimmunol.170.3.1249","article-title":"Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection","volume":"170","author":"Jinushi","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib131","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijmm.2007.07.003","article-title":"Mechanisms of dendritic cell-based vaccination against infection","volume":"298","author":"Fajardo-Moser","year":"2008","journal-title":"Int. J. Med. Microbiol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib132","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1016\/j.vaccine.2006.04.010","article-title":"The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu","volume":"24","author":"Salem","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.cellimm.2010.03.002_bib133","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.4049\/jimmunol.171.8.4320","article-title":"Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses","volume":"171","author":"Lore","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib134","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/eji.200323797","article-title":"Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines","volume":"33","author":"Edwards","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib135","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.4049\/jimmunol.170.8.4102","article-title":"A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells","volume":"170","author":"Datta","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib136","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1084\/jem.194.6.863","article-title":"Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens","volume":"194","author":"Kadowaki","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2010.03.002_bib137","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1126\/science.1099153","article-title":"Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling","volume":"305","author":"West","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2010.03.002_bib138","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/13543784.17.7.1051","article-title":"Clinical investigations of Toll-like receptor agonists","volume":"17","author":"Meyer","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.cellimm.2010.03.002_bib139","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/intimm\/dxp053","article-title":"PolyI:C-induced reduction in uptake of soluble antigen is independent of dendritic cell activation","volume":"21","author":"Tirapu","year":"2009","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib140","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1016\/j.vaccine.2009.01.071","article-title":"Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer","volume":"27","author":"Jasani","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.cellimm.2010.03.002_bib141","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00262-008-0489-2","article-title":"Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7\/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration","volume":"57","author":"Boullart","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cellimm.2010.03.002_bib142","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4049\/jimmunol.177.1.298","article-title":"TLR activation of langerhans cell-like dendritic cells triggers an antiviral immune response","volume":"177","author":"Renn","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib143","doi-asserted-by":"crossref","DOI":"10.1002\/eji.200635854","article-title":"Modification of TLR-induced activation of human dendritic cells by type I IFN: synergistic interaction with TLR4 but not TLR3 agonists","author":"Walker","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib144","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.vaccine.2008.10.024","article-title":"A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro","volume":"27","author":"Navabi","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.cellimm.2010.03.002_bib145","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0264-410X(02)00599-6","article-title":"Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R)","volume":"21","author":"Adams","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.cellimm.2010.03.002_bib146","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1158\/0008-5472.CAN-04-1261","article-title":"Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity","volume":"64","author":"Mailliard","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib147","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.onc.1210906","article-title":"Toll-like receptors and immune regulation: implications for cancer therapy","volume":"27","author":"Wang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.cellimm.2010.03.002_bib148","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1158\/1078-0432.CCR-07-1378","article-title":"Toll-like receptors in tumor immunotherapy","volume":"13","author":"Paulos","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib149","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1365-2672.2008.03896.x","article-title":"TLRs antiviral effect on hepatitis B virus in HepG2 cells","volume":"105","author":"Xia","year":"2008","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib150","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/JVI.02008-08","article-title":"Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells","volume":"83","author":"Guo","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib151","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1073\/pnas.0510801103","article-title":"Activation of anti-hepatitis C virus responses via Toll-like receptor 7","volume":"103","author":"Lee","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellimm.2010.03.002_bib152","doi-asserted-by":"crossref","DOI":"10.1111\/j.1462-5822.2009.01353.x","article-title":"Lipopolysaccharide induced innate immune responses in primary hepatocytes down-regulates woodchuck hepatitis virus replication via interferon-independent pathways","author":"Zhang","year":"2009","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib153","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hep.20839","article-title":"Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection","volume":"42","author":"Horsmans","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib154","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2893.2007.00898.x","article-title":"Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy","volume":"15","author":"Schott","year":"2008","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.cellimm.2010.03.002_bib155","first-page":"702","article-title":"Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease","volume":"7","author":"Fletcher","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.cellimm.2010.03.002_bib156","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/15257770701490472","article-title":"Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine","volume":"26","author":"Xiang","year":"2007","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.cellimm.2010.03.002_bib157","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22321","article-title":"Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C","volume":"48","author":"Roberts","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib158","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/hep.21773","article-title":"Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus","volume":"46","author":"McHutchison","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cellimm.2010.03.002_bib159","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11060-008-9693-3","article-title":"A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)","volume":"91","author":"Butowski","year":"2009","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11060-008-9705-3","article-title":"A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas","volume":"91","author":"Butowski","year":"2009","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib161","first-page":"3005","article-title":"Polyinosinic-polycytidylic acid complexed with poly-l-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects","volume":"52","author":"Ewel","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib162","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1227\/00006123-199606000-00006","article-title":"Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study","volume":"38","author":"Salazar","year":"1996","journal-title":"Neurosurgery"},{"key":"10.1016\/j.cellimm.2010.03.002_bib163","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-5-10","article-title":"Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models","volume":"5","author":"Zhu","year":"2007","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cellimm.2010.03.002_bib164","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.micinf.2007.06.007","article-title":"Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge","volume":"9","author":"Ichinohe","year":"2007","journal-title":"Microbes Infect."},{"key":"10.1016\/j.cellimm.2010.03.002_bib165","doi-asserted-by":"crossref","unstructured":"Mismatched double-stranded RNA: polyI:polyC12U, Drugs R D 5 (2004) 297\u2013304.","DOI":"10.2165\/00126839-200405050-00006"},{"key":"10.1016\/j.cellimm.2010.03.002_bib166","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jir.1992.1992.85","article-title":"A comparison of interferon responses to poly ICLC in males and females","author":"Bever","year":"1992","journal-title":"J. Interferon Res. Spec. No."},{"key":"10.1016\/j.cellimm.2010.03.002_bib167","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1128\/MCB.15.4.2207","article-title":"Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways","volume":"15","author":"Megyeri","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cellimm.2010.03.002_bib168","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.hepres.2005.10.005","article-title":"Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication","volume":"34","author":"Koyama","year":"2006","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.cellimm.2010.03.002_bib169","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1386-6346(02)00020-7","article-title":"Different antiviral activities of IFN-alpha subtypes in human liver cell lines: synergism between IFN-alpha2 and IFN-alpha8","volume":"24","author":"Yamamoto","year":"2002","journal-title":"Hepatol. Res."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000887491000064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000887491000064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:44:48Z","timestamp":1757803488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000887491000064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":169,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"alternative-id":["S000887491000064X"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2010.03.002","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2010.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}